Downregulation of microRNA-324-3p inhibits lung cancer by blocking the NCAM1-MAPK axis through ALX4
Related Experiment Video
Updated: Dec 4, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Tieniu Song1, Hui Zhou2, Xiaoping Wei3
1Department of Thoracic Surgery, West China Hospital, Sichuan University, 610000, Chengdu, P.R. China. academy123@163.com.
Abstract:
Lung cancer remains the principal cause of cancer-related death worldwide. As microRNAs (miRNAs) are critically involved in lung cancer, we investigated the potential role of miR-324-3p in lung cancer via the ALX4/NCAM1/MAPK axis. The expression of miR-324-3p and ALX4 was detected in clinical samples, and their interaction confirmed by miRNA-targeted luciferase reporter assay. The mechanisms involved in the miR-324-3p-ALX4 interaction in lung cancer cell biological processes were analyzed through gain- and loss-of function approaches. In addition, cultured lung cancer cells were treated with the p38MAPK pathway activator P79350 in order to explore the role of this pathway in the abovementioned axis. Further, a tumor xenograft model in nude mice was constructed to confirm the in vitro findings. miR-324-3p was highly expressed in lung cancer tissues and cells, and inhibited the expression of ALX4 in A549 cells. After confirming the targeted inhibition of ALX4 by miR-324-3p, we showed that this interaction upregulated the expression of NCAM1 and activated the MAPK pathway. The inhibition of miR-324-3p could suppress lung cancer cell invasion, migration, and autophagy, and retarded the growth of subcutaneous tumors in nude mice. Downregulation of ALX4 or NCAM1 overexpression reversed these favorable effects of decreased miR-324-3p. Our study demonstrated the promotive effect of miR-324-3p on the development and progression of lung cancer, thus suggesting a new target for treatment of this devastating disease.
Insights
MicroRNA-324-3p (miR-324-3p) promotes lung cancer progression by inhibiting ALX4, activating the MAPK pathway, and increasing cell invasion. Inhibiting miR-324-3p offers a potential therapeutic strategy for lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Lung cancer is a leading cause of cancer mortality globally.
- MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
- The specific role of miR-324-3p in lung cancer requires further elucidation.
Purpose of the Study:
- To investigate the role of miR-324-3p in lung cancer.
- To explore the underlying molecular mechanisms involving the ALX4/NCAM1/MAPK axis.
- To identify miR-324-3p as a potential therapeutic target for lung cancer.
Main Methods:
- Expression analysis of miR-324-3p and ALX4 in clinical lung cancer samples.
- Luciferase reporter assays to confirm the interaction between miR-324-3p and ALX4.
- In vitro gain- and loss-of-function studies in lung cancer cell lines.
- In vivo tumor xenograft model in nude mice.
- Analysis of the MAPK pathway activation.
Main Results:
- miR-324-3p was significantly upregulated in lung cancer tissues and cells.
- miR-324-3p directly inhibited ALX4 expression, leading to NCAM1 upregulation and MAPK pathway activation.
- Inhibition of miR-324-3p suppressed lung cancer cell invasion, migration, and autophagy.
- Reduced miR-324-3p expression retarded tumor growth in vivo.
- Reversal of these effects was observed upon ALX4 downregulation or NCAM1 overexpression.
Conclusions:
- miR-324-3p promotes lung cancer development and progression through the ALX4/NCAM1/MAPK axis.
- Targeting miR-324-3p presents a promising therapeutic strategy for lung cancer treatment.
Related Concept Videos
MicroRNAs
MicroRNAs
lncRNA - Long Non-coding RNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

